Surface Oncology, Inc.
Anti-IL-27 antibodies and uses thereof

Last updated:

Abstract:

The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Status:
Grant
Type:

Utility

Filling date:

22 Mar 2019

Issue date:

17 May 2022